LUCAR G39P
Alternative Names: LUCAR-G39PLatest Information Update: 05 Apr 2024
Price :
$50 *
At a glance
- Originator Nanjing Legend Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 06 Mar 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT06295549)